Skip to main content

Table 6 Adjusted odds ratios of physical independence and normal functionat 12 months.

From: Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low – results from RABBIT, the German biologics register

  Achievement of FFbH ≥67 (physical independence) Achievement of FFbH ≥83 (functional remission)
  Univariate Multivariate Univariate Multivariate
  OR 95% CI Adj. OR 95% CI OR 95% CI Adj. OR 95% CI
FFbHa 1.54 1.23–1.92 1.51 1.20–1.90 1.84 1.51–2.23 1.85 1.50–2.29
Propensity score (scale: 0 to 1)b 0.96 0.85–1.09    0.93 0.84–1.04 0.85 0.74–0.98
Rheumatoid factor positive 0.99 0.51–1.90    0.67 0.38–1.16   
Number of previous DMARDs         
4 to 5 versus 2 to 3 0.73 0.44–1.20 0.67 0.39–1.15 0.52 0.31–0.86   
≥6 versus 2 to 3 0.40 0.17–0.94 0.39 0.16–0.94 0.50 0.23–1.10   
Swollen joint count 1.03 0.99–1.07    1.01 0.97–1.05   
Tender joint count 1.01 0.97–1.04    0.98 0.95–1.01   
ESRa 0.96 0.86–1.06    0.95 0.86–1.05   
DAS28 1.08 0.86–1.34    0.90 0.74–1.10   
Pain (0 to 10) 1.05 0.92–1.19    1.02 0.91–1.15 1.22 1.05–1.40
Female 0.79 0.44–1.40    0.94 0.53–1.68   
Agea 0.70 0.56–0.88    0.62 0.51–0.76 0.64 0.51–0.80
Disease duration (years) 0.95 0.92–0.98    0.94 0.91–0.97   
Disease duration ≤2 years versus >2 years 1.21 0.39–3.78    1.59 0.64–3.96   
Any comorbidity, yes versus no 0.38 0.23–0.62 0.42 0.25–0.71 0.46 0.28–0.73   
Osteoporosis, yes versus no 0.47 0.27–0.83    0.43 0.24–0.78   
BIOL versus CON 2.63 1.22–5.69 3.88 1.71–8.79 1.68 0.89–3.19 2.18 1.04–4.57
Anti-TNF agents versus CON 2.77 1.28–6.00 4.09 1.80–9.29 1.73 0.91–3.29 2.21 1.06–4.63
Anakinra versus CON 0.57 0.07–4.83 0.79 0.09–7.20 0.82 0.17–3.88 1.33 0.26–6.94
  1. The achievement of FFbH ≥67 was investigated only in severely disabled patients with high risk of needing external help (FFbH ≤50, cutoff point used to identify severely disabled patients with a high risk of needing external help) [13] before the start of treatment (BIOL, n = 452 (anti-TNF agents, n = 425; anakinra, n = 27); CON, n = 100); the achievement of FFbH >83 was investigated only in patients who were at any risk of needing external help (FFbH <67, cut-off point used to identify patients who were under any increased risk of needing external help) [13], (BIOL, n = 682 (anti-TNF agents, n = 643; anakinra, n = 39); CON, n = 173). Results of different univariate and multivariate logistic regression analyses. Final multivariate models were found by stepwise regression. aThe ORs refer to 10 units of the parameter. bOR refer to 0.1 units of the propensity score. Adj. OR, adjusted odds ratio; BIOL, patients treated with biologics; CI, confidence interval; CON, patients receiving conventional DMARD treatment (control group); CRP, C-reactive protein; DAS28, disease activity score based on 28 joint counts; DMARD, disease modifying anti-rheumatic drugs; ESR, erythrocyte sedimentation rate; FFbH, Funktionsfragebogen Hannover (Hannover Functional Status Questionnaire); TNF, tumor necrosis factor.